Astellas Pharma Inc. and 4D Molecular Therapeutics, entered into a license agreement under which Astellas gains rights to utilize 4DMT’s intravitreal retinotropic R100 vector for one genetic target implicated in rare monogenic ophthalmic disease(s), with options to add up to two additional targets. R100 is an adeno-associated virus (AAV) vector for intravitreal delivery. It has the ability to penetrate the internal limiting membrane barrier and to efficiently transduce the entire retina...